Sapreme Technologies is Enabling endosomal escape of macromolecule therapeutics.
Sapreme Technologies has raised €22M across 2 funding rounds from 3 investors, most recently a Series A round in Oct 2021. Based in Utrecht, Netherlands; founded 2016; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2021-10-11 | Series A | €15M | Aglaia Oncology Funds,Private Investors | View deal → |
| 2019-01-01 | Other | €6.8M | Horizon 2020 | View deal → |
